The US drug firm had been search for a site since March.
According to North Carolina Governor Roy Cooper, Pfizer will spend $100m (€85m) on the new facility and has also committed $4m to support postdoctoral fellowships in North Carolina universities for training in gene therapy research.
The project will create jobs that deliver “a total payroll impact of more than $3.9m each year to the community” according to the North Carolina Department of Commerce and the Economic Development Partnership.
The project will be part funded by a $250,000 grant previously awarded to Wyeth – which was acquired by Pfizer in 2009 - by the One North Carolina Fund, which helps local Governments attract economic investment.
A Pfizer spokeswoman confirmed the story but declined to comment further, telling us "Pfizer recently announced that we’re moving forward with plans to invest in a new gene therapy manufacturing facility in Sanford. This work is still in the preliminary stages and we aren’t able to share additional detail at this time."
The decision follows a little over a year after the US drug manufacturer acquired Bamboo Therapeutics, a North Carolina-based gene therapy developer.
The deal included a recombinant Adeno-Associated Virus (rAAV) vector design and production technology, a Phase I candidate for Giant Axonal Neuropathy and a preclinical programme targeting Duchenne Muscular Dystrophy (DMD).
Pfizer also gained a 11,000sq ft gene therapy manufacturing facility in Chapel Hill that Bamboo bought from the University of North Carolina in 2016.